Clinical Trial

Cannabidivarin (CBDV) vs. Placebo in Children With Autism Spectrum Disorder (ASD)

Name: Cannabidivarin (CBDV) vs. Placebo in Children With Autism Spectrum Disorder (ASD) — clinical trial record (NCT03202303)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

This trial aims to study the efficacy and safety of cannabidivarin (CBDV) in children with ASD.

Protocol Amendment History 22 amendments

This ClinicalTrials.gov record has been amended 22 times since 2017-06-27; most recent amendment 2025-10-20.

Status change: Not Yet Recruiting → Recruiting 2019-04-22

Trial Details

NCT Number	NCT03202303
Lead Sponsor	Montefiore Medical Center Collaborators: United States Department of Defense, GW Pharmaceuticals Ltd, Jazz Pharmaceuticals
Conditions	Autism Spectrum Disorder
Enrollment	100 participants
Start Date	2019-04-12
Primary Completion	2027-02 (estimated)
Study Completion	2027-02 (estimated)
Updated on ClinicalTrials.gov	2025-10-22